Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial
In brief
Partial-breast radiation had 1% five-year recurrence, versus 0.8% with whole-breast
In a randomized trial of 3,309 patients with low-risk invasive breast cancer, recurrence in the treated breast at five years was 1.0% with partial-breast radiation and 0.8% with whole-breast radiation. The difference was under 0.2 percentage points, but the trial did not formally establish noninferiority; partial-breast treatment remains a reasonable alternative, with that statistical uncertainty to keep in mind.
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Q1)
- Published
- 17 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Bruno Meduri, Antonella Baldissera, Cinzia Iotti, Luc J E E Scheijmans, Marcel R Stam, Salvatore Parisi, et al.
- PMID
- 43044095
- DOI
- 10.1200/JCO-26-00969
Why clinicians should know about it
- Picked for Breast and Endocrine Surgery (paper of the day, 18 November 2026): Randomized trial informs radiotherapy after breast-conserving surgery
- Picked for Radiation Oncology (paper of the day, 18 November 2026): Randomized phase III comparison of partial- and whole-breast irradiation
Abstract
PURPOSE: The aim of this study was to investigate whether external-beam accelerated partial-breast irradiation (APBI) provides noninferior local control compared with whole-breast irradiation (WBI). PATIENTS AND METHODS: We conducted this randomized phase III trial (ClinicalTrials.gov identifier: NCT01803958) in 35 centers. Patients age ≥49 years with invasive breast cancer, resection margins ≥2 mm, tumor diameter ≤3 cm, and pN0-1 were randomly assigned 1:1 to WBI or APBI (38.5 Gy in 10 fractions twice daily). Neither patients nor investigators were masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence (IBTR), analyzed according to the modified intention-to-treat analysis. We assumed a 5-year IBTR rate of 4% in the WBI group to exclude a 2% increase in the APBI group (90% power; noninferiority margin hazard ratio [HR], 1.5). RESULTS: Between 2007 and 2019, 3,309 patients were randomly assigned (1,652 to APBI, 1,657 to WBI); 84 were excluded from the analysis. The median follow-up was 97.5 months. The 5-year cumulative IBTR incidence was 1.0% (95% CI, 0.6 to 1.6) for APBI and 0.8% (95% CI, 0.5 to 1.4) for WBI. The HR for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20) with the upper confidence limit crossing the prespecified noninferiority margin. CONCLUSION: At 5 years, the cumulative incidence of IBTR is exceptionally low (≤1%) in both arms. Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%. External-beam APBI therefore is a reasonable clinical alternative to WBI for low-risk patients.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.